Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in B- and T-cell lymphomas

R P Gale1, T A Waldmann, J O Armitage

  • 1Salick Health Care, Inc., Los Angeles, CA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Clinical characteristics of vulnerable populations hospitalized and diagnosed with COVID-19 in Buenos Aires, Argentina.

Scientific reports·2021
Same author

Clinical characteristics of vulnerable populations hospitalized and diagnosed with COVID-19 in Buenos Aires, Argentina.

Scientific reports·2021
Same author

Agents' beliefs and economic regimes polarization in interacting markets.

Chaos (Woodbury, N.Y.)·2018
Same author

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Real and financial market interactions in a multiplier-accelerator model: Nonlinear dynamics, multistability and stylized facts.

Chaos (Woodbury, N.Y.)·2017
Same author

[RECONSTRUCTING THE LIFE OF AN UNKNOWN MAN--INTERDISCIPLINARY APPROACH].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

This review highlights advances in understanding T- and B-cell lymphoma biology, focusing on corrupted cell development pathways. Future research will explore optimal treatment strategies, including intensive versus less intensive therapies and the role of immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Significant progress has been made in understanding the underlying biology of human T-cell and B-cell lymphomas.
  • Research has elucidated how normal B-cell and T-cell development processes are disrupted in lymphomas.

Framework:

  • The review examines how these developmental abnormalities in lymphomas can be targeted or potentially reversed through therapeutic interventions.
  • Understanding these corrupted pathways is crucial for developing novel treatment strategies.

Implementation:

  • Current therapeutic progress for lymphomas is less pronounced than biological understanding.
  • Key clinical questions involve determining the efficacy of intensive versus less intensive treatment regimens.
  • The potential utility of immunotherapies for treating T- and B-cell lymphomas is under active investigation.

Related Experiment Videos

Implications:

  • This work informs ongoing research and clinical discussions on lymphoma treatment optimization.
  • Future directions include evaluating the benefits of different therapeutic intensities and exploring novel immune-based approaches.
  • The findings set the stage for discussions at the upcoming 1996 B and T-cell lymphoma meeting.